Bristol Myers Squibb
As of the edition of 20 October 2026, Bristol Myers Squibb runs 393 drugs, 140 of them marketed; it is on route A at 72 targets and on route B at 39 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Bristol Myers Squibb was renamed in 1998.
The records place 17 company names in this family.
- BRISTOL MYERS CO: renamed in 1998
- ZymoGenetics: acquired in 2010; successor BRISTOL MYERS CO
- Celgene: acquired in 2019
- Celgene Corporation, a Bristol-Myers Squibb Company: acquired in 2019; successor BRISTOL MYERS CO
- MyoKardia, Inc.: acquired in 2020; successor BRISTOL MYERS CO
- Turning Point Therapeutics, Inc.: acquired in 2022; successor BRISTOL MYERS CO
- RayzeBio, Inc.: acquired in 2024; successor BRISTOL MYERS CO
- 2seventy bio: acquired in 2025; successor BRISTOL MYERS CO
- MIRATI THERAPEUTICS, INC.: acquired
Drugs by status
| Status | Count |
|---|---|
| Marketed | 140 |
| Active | 56 |
| Went quiet | 61 |
| Stopped | 108 |
| Status not established | 28 |
| Total | 393 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Paclitaxel | none listed | 0 |
| Cyclophosphamide anhydrous | none listed | 0 |
| Cisplatin | none listed | 0 |
| Carboplatin | none listed | 0 |
| Dexamethasone | none listed | 5 |
| Metformin | none listed | 4 |
| Nivolumab | Ends 2031 (orphan exclusivity) | 2 |
| Etoposide | none listed | 5 |
| Lenalidomide | Ends 2027 (patent) | 0 |
| Ipilimumab | Ends 2027 (orphan exclusivity) | 1 |
| Azacitidine | Ends 2029 (exclusivity) | 4 |
| Tislelizumab | Ends 2036 (computed from the first US licence) | 2 |
| Dapagliflozin | Ends 2029 (patent) | 2 |
| Ifosfamide | none listed | 0 |
| Thalidomide | none listed | 0 |
| Acetylcysteine | none listed | 0 |
| Dasatinib anhydrous | Ended 2026 (exclusivity) | 12 |
| Pomalidomide | Ends 2031 (patent) | 0 |
| Warfarin | none listed | 1 |
| Cabozantinib | Ends 2032 (exclusivity) | 2 |
| Estradiol | Ends 2032 (patent) | 6 |
| Apixaban | Ends 2028 (exclusivity) | 2 |
| Efavirenz | none listed | 0 |
| Testosterone | none listed | 4 |
| Entecavir anhydrous | none listed | 0 |
A route B row is one company at one target. 115 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 72 targets, route B at 39 targets.
All 111 rows on route A or B
In the product111 company-target rows on route A or B; 108 are not shown here, and no score is.
See all 111 targets where Bristol Myers Squibb needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 610 trials led
- Immune system: 342 trials led
- Blood and lymph: 329 trials led